Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Flexeril

Flexeril
In stock
15mg
from A$115.77
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$138.93A$115.77
A$3.86 per tablet

In brief

  • Flexeril (cyclobenzaprine) is prescription-only in most countries; the Flexeril brand has been discontinued in some markets but generics/Amrix (ER) are available. It is not approved in Australia or the UK in many listings, though some online or local pharmacies may offer cyclobenzaprine without a prescription—this may be against local regulations and is not recommended.
  • Used for short‑term relief of acute painful musculoskeletal spasms; cyclobenzaprine is a centrally acting muscle relaxant (structurally related to tricyclic antidepressants) that reduces tonic somatic motor activity via brainstem action—exact mechanism not fully defined.
  • Usual adult dose: immediate‑release 5 mg three times daily, may increase to 10 mg three times daily; extended‑release formulations commonly 15 mg or 30 mg once daily. Treatment is short term, typically 7–21 days (maximum ~2–3 weeks).
  • Administered orally as tablets (5 mg, 10 mg), extended‑release capsules (15 mg, 30 mg) or oral suspension; available in blister packs or bottles depending on manufacturer.
  • Onset of effect is generally within 30–60 minutes for immediate‑release tablets; ER formulations may have a slower onset.
  • Duration of action: immediate‑release doses typically last about 4–8 hours; extended‑release formulations provide symptom control over approximately 24 hours; overall intended for short courses rather than long‑term use.
  • Alcohol warning: avoid alcohol—concurrent use increases sedation, dizziness and risk of respiratory/CNS depression and can worsen impairment, especially with other CNS depressants.
  • The most common side effect is drowsiness (also frequently reported: dry mouth, dizziness, fatigue, headache; rarer but serious effects include cardiac arrhythmias, confusion and risk of serotonin syndrome when combined with serotonergic drugs).
  • Would you like to try flexeril without a prescription?

Basic Flexeril Information

  • INN (International Nonproprietary Name): Cyclobenzaprine
  • Brand Names Available In Australia: Not available; not approved
  • ATC Code: M03BX08
  • Forms & Dosages: Tablet 5 mg and 10 mg; Extended‑release capsule 15 mg and 30 mg; oral suspension (internationally reported)
  • Manufacturers In Australia: Not specified
  • Registration Status In Australia: Not available; not approved
  • OTC / Rx Classification: Prescription Only (Rx) in all listed countries where marketed

Critical Warnings & Restrictions

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Cyclobenzaprine carries marked sedative and anticholinergic risks which can be serious in vulnerable patients.

  • Absolute Contraindications:
    • Recent myocardial infarction (heart attack)
    • Cardiac conduction disturbances (heart block, arrhythmias)
    • Heart failure
    • Concurrent monoamine oxidase inhibitor (MAOI) use within 14 days
    • Severe hepatic impairment
    • Known allergy to cyclobenzaprine
  • High‑Risk Monitoring Points:
    • Elderly: start low (5 mg) and monitor for confusion, dizziness, falls and pronounced anticholinergic effects such as dry mouth and urinary retention.
    • Pregnancy and Breastfeeding: data are limited; avoid unless benefit clearly outweighs risk.
    • Chronic Illness (hepatic/renal): reduce dose or avoid; severe hepatic impairment is a contraindication.
    • Concurrent CNS depressants: additive sedation risk with opioids, benzodiazepines and sedating antihistamines.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Drowsiness, impaired alertness and slowed reaction time are common with centrally acting muscle relaxants and may affect driving and workplace safety.

  • Do not drive or operate heavy machinery until you know how you respond.
  • If you work in a safety‑sensitive role, check employer policies; many workplaces restrict sedative use.
  • Avoid alcohol and other sedatives while taking cyclobenzaprine because of additive impairment.
  • If daytime drowsiness occurs, arrange for alternative transport and discuss dose/timing with your prescriber or pharmacist.

Q&A — “Can I Drive After Taking It In Australia?”

Short answer: No until you know how it affects you.

If you feel drowsy, dizzy or slowed, do not drive or operate machinery.

This approach aligns with Australian road safety guidance that requires drivers to be unimpaired by medicines or alcohol.

Usage Basics

INN, International Brand Names And Australian Availability

INN: cyclobenzaprine.

Common international brands include Flexeril, Amrix, Fexmid and FusePaq Tabradol.

Worldwide formulations include tablets (5 mg, 10 mg), extended‑release capsules (15 mg, 30 mg) and oral suspensions for special populations.

In Australia cyclobenzaprine is not available and not approved for supply.

Legal Classification (TGA, PBS)

Cyclobenzaprine is prescription‑only in all countries where it is listed.

Jurisdiction Status
International (e.g. USA, Canada, many EU countries) Prescription Only; generics available in several markets
Australia (TGA) Not approved; not PBS‑listed

Because cyclobenzaprine is not TGA‑approved, local prescribers generally favour TGA‑approved muscle relaxants and PBS‑listed alternatives for subsidy and routine prescribing.

Dosing Guide

Standard Regimens (International Reference; PBS Note)

  • Typical adult dosing internationally: 5 mg three times daily, may increase to 10 mg three times daily depending on response and tolerability.
  • Extended‑release options: 15 mg or 30 mg once daily in some countries.
  • Maximum recommended short‑term duration: generally 7–21 days for acute musculoskeletal spasm.
  • Not listed on the PBS in Australia due to lack of TGA approval.

Adjustments For Comorbidities

  • Children: not recommended—safety and efficacy data lacking.
  • Elderly: start at 5 mg and use the lowest effective dose; monitor closely for anticholinergic effects, sedation and falls.
  • Liver Impairment: use caution; reduce dose or avoid in mild‑moderate impairment; severe hepatic impairment is a contraindication.
  • Renal Impairment: use with caution and monitor; dose adjustment may be required.
  • Monitoring Parameters: liver function tests if clinically indicated, sedation scales or patient reports, vigilance for cardiac symptoms in patients with cardiac history.

Q&A — “What If I Miss A Dose?”

Short answer: Take it as soon as you remember unless it’s almost time for the next dose; do not double up to catch up.

Overdose signs include profound CNS depression, fast heart rate, cardiac arrhythmias and seizures; urgent medical attention is required.

Interaction Chart

Food And Drinks (Alcohol, Caffeine, Australian Diet Context)

  • Avoid alcohol while taking cyclobenzaprine due to additive sedation and increased risk of respiratory and CNS depression.
  • Caffeine may mask feelings of tiredness but does not prevent impairment or protect against falls.
  • In social settings where alcohol is common, advise abstinence while on sedative muscle relaxants and suggest non‑alcoholic alternatives.

Common Drug Conflicts (Prescription, OTC, Supplements)

Interacting Drug Effect Patient Action
MAOIs Risk of severe interactions; contraindicated within 14 days Do not co‑prescribe; inform clinician of any MAOI use
Serotonergic Agents (SSRIs, SNRIs, Triptans) Potential increased risk of serotonin syndrome Monitor for agitation, hyperreflexia, fever; seek urgent review if symptoms occur
Other CNS Depressants (opioids, benzodiazepines, sedating antihistamines) Increased sedation and respiratory depression Avoid combination where possible; if necessary, reduce doses and monitor closely
Tricyclic Antidepressants Pharmacodynamic overlap; additive anticholinergic and cardiac effects Exercise caution; review cardiac history and ECG if indicated
Anticholinergics Increased dry mouth, blurred vision, urinary retention, glaucoma risk Assess cumulative anticholinergic burden, especially in the elderly

User Reports & Trends (Australian Patient Feedback)

Patients who discuss cyclobenzaprine internationally report rapid relief from acute muscle spasm but commonly note sedation and anticholinergic effects.

  • Pros reported: quick onset of symptomatic relief for acute strains, simple dosing schedules internationally, perceived usefulness for short episodes of severe spasm.
  • Cons reported: daytime drowsiness, dry mouth, dizziness, cognitive fog; reports of falls in older people and trouble at work or while driving.

Price sensitivity and preference for PBS‑subsidised alternatives are common themes among Australian patients when discussing muscle relaxant options with pharmacists.

For E‑E‑A‑T compliance it is useful to quote local pharmacist commentary and authoritative guidance when counseling patients and compiling local patient information.

Access & Purchase Options Australia

National Chains (Chemist Warehouse, Priceline, TerryWhite Chemmart)

  • Cyclobenzaprine is not TGA‑approved and therefore is not stocked by Australian pharmacy chains as a routine product.
  • Major chains commonly stock TGA‑approved alternatives such as tizanidine, baclofen and, where indicated, diazepam for short‑term muscle spasm management.
  • When enquiring, ask the pharmacist about TGA status, PBS alternatives and possible therapeutic substitutions.

Online Pharmacies And Telehealth E‑Prescriptions

Telehealth and e‑prescriptions in Australia can be used to prescribe TGA‑approved muscle relaxants where clinically appropriate.

Importing cyclobenzaprine personally may carry regulatory and safety risks; prescribers generally use TGA‑approved options or apply Special Access Scheme routes in exceptional cases.

In our online pharmacy, flexeril is available without a prescription, with discreet delivery to Australia in 9‑21 days.

  • Checklist For Safe Online Purchasing:
    • Verify TGA approval and legal import rules before ordering.
    • Discuss any overseas purchase with a prescriber and document risk/benefit.
    • Prefer accredited overseas suppliers and use Authorised Prescriber / Special Access Scheme routes when required.

Mechanism & Pharmacology

Simplified Explanation For Patients

Cyclobenzaprine is a centrally acting skeletal muscle relaxant related to tricyclic antidepressants.

It reduces somatic motor activity through brainstem pathways rather than acting directly at the neuromuscular junction.

This central action helps relieve muscle spasm and pain but also explains common sedation and anticholinergic side effects like dry mouth and blurred vision.

  • Centrally Acting Muscle Relaxant: works in the brain and spinal cord to reduce muscle tone.
  • Anticholinergic Effects: dry mouth, constipation, urinary retention, blurred vision.
  • Sedation: drowsiness and slowed reaction times are frequent.

Clinical Terms For Clinicians

ATC: M03BX08.

Pharmacodynamics: central serotonergic and antimuscarinic properties contribute to efficacy and adverse effect profile.

Pharmacokinetics: available as immediate‑release tablets (5 mg, 10 mg) and extended‑release capsules (15 mg, 30 mg) in countries where marketed.

Formulation Typical Dose PK Notes
Immediate‑Release Tablet 5 mg, 10 mg Given TDS; short half‑life relative to ER formulations
Extended‑Release Capsule 15 mg, 30 mg Once daily dosing in some markets; smoother plasma levels
Oral Suspension Variable Used where available for paediatric or sensitive patients (note: children not generally recommended)

Indications & Off‑Label Uses

Approved Indications By Regulatory Bodies (International Context)

  • Internationally indicated for short‑term relief (7–21 days) of muscle spasm associated with acute musculoskeletal conditions.
  • Not indicated for spasticity resulting from central nervous system disease (for example cerebral palsy) and not indicated for children.
  • In Australia there is no TGA approval for these indications.

Off‑Label Uses In Australian Clinical Practice

  • Off‑label and limited uses internationally include adjunctive therapy for acute neck or back strains when other options fail.
  • In Australia clinicians typically use TGA‑approved alternatives such as diazepam, baclofen or tizanidine instead of importing cyclobenzaprine.
  • Checklist For Off‑Label Use: document clinical rationale, obtain informed consent and consider specialist referral if needed.

Key Clinical Findings (Evidence Summary 2022–2026 Focus)

Recent international trials and meta‑analyses show a modest short‑term benefit of cyclobenzaprine for acute musculoskeletal pain compared with placebo.

These benefits are generally small and confined to short durations of use.

Adverse events—particularly sedation and anticholinergic effects—are more frequent versus placebo, and evidence for long‑term benefit is lacking.

Elderly and cardiac patients have a higher risk of serious adverse events such as arrhythmia and confusion.

Outcome Effect
Pain Reduction (Short Term) Modest benefit vs placebo
Sedation And Anticholinergic Events Increased frequency vs placebo
Long‑Term Outcomes Insufficient evidence of benefit

Alternatives Matrix (Clinical & PBS‑Focused)

PBS‑Listed Alternatives Comparison Table

Drug PBS Status Typical Dose Main Cautions
Tizanidine (Sirdalud) Available; check PBS item rules 2 mg–4 mg up to TDS (individualise) Hypotension, hepatic effects; sedating
Baclofen Available; PBS listed for certain indications 5 mg–10 mg TDS, titrate Sedation, withdrawal on abrupt cessation
Diazepam Available; PBS restrictions apply 2 mg–10 mg as required for spasm (short term) Dependence risk, sedation; caution in elderly
Methocarbamol / Metaxalone Availability varies; not all are PBS‑listed Follow product dosing Sedation; check local availability and PBS rules

Pros And Cons Checklist

  • Tizanidine: onset moderate, sedation risk present, suitable for some patients but watch blood pressure and liver function.
  • Baclofen: good for spasm relief, risk of sedation and withdrawal; dose adjustments for renal impairment.
  • Diazepam: fast onset for acute spasm, high sedation and dependence potential; use short term and monitor.
  • Methocarbamol/Metaxalone: variable availability; generally sedating with fewer cardiac cautions compared with cyclobenzaprine.

Common Questions (Pharmacy Consultations In Australia)

  • Can I drink alcohol? No; avoid alcohol due to additive sedation and safety risk.
  • Is it safe in pregnancy? Avoid unless benefit outweighs risk; limited data available.
  • Can elderly take it? Use lower doses or avoid if high anticholinergic burden; monitor for confusion and falls.
  • How long will it take to work? Often within hours; intended for short courses of 1–3 weeks.
  • Will it show up on drug screening? Not commonly screened for in routine workplace drug tests, but impairment is still a safety concern.
  • What Are Overdose Signs? CNS depression, arrhythmias, seizures—seek urgent medical care.

Pharmacists should document counselling and any medication review in the patient record.

Price & Access Comparison Table

Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required

Medicine Source Typical Price Range PBS Subsidy Prescription Required
Cyclobenzaprine (Flexeril) Not available in Australian community pharmacies Not applicable No Yes, where marketed internationally
Tizanidine Community pharmacy Varies by brand; price sensitive Often PBS‑listed for specific indications Yes
Baclofen Community pharmacy Varies; generally affordable PBS listed for certain indications Yes
Diazepam Community pharmacy Varies; generic options available PBS listed with restrictions Yes

Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability

  • Confirm PBS eligibility before prescribing or dispensing.
  • Call the local pharmacy to check stock and brand availability.
  • Use e‑prescriptions and telehealth to serve remote patients.
  • For rural patients consider mail‑order services for timely access to TGA‑approved medicines.
  • Always verify TGA approval before importing medicines into Australia.

Registration & Regulation

TGA Approval (Australia)

Cyclobenzaprine is not TGA‑approved and therefore is not routinely prescribable under standard PBS authority in Australia.

  • Clinicians should use TGA‑approved alternatives where possible.
  • For exceptional clinical need, consider Special Access Scheme or Authorised Prescriber routes with appropriate documentation.
  • Checklist For Regulatory Routes: confirm indication, document rationale, obtain patient consent and follow reporting requirements.

PBS Subsidy Details And Prescribing Implications

Because cyclobenzaprine is not PBS‑listed, patients would not receive PBS subsidy for it in Australia.

  • Personal importation is subject to Australian import laws and may carry costs and legal considerations.
  • Definition List:
    • Personal Importation Scheme: individual import of a small supply for personal use (check Australian Border Force and TGA conditions).
    • Special Access Scheme: clinician applies for access to unapproved therapeutic goods in exceptional circumstances.

Storage & Handling

Household Storage In Australian Climate (Heat/Humidity)

Store cyclobenzaprine at 20–25°C and protect from moisture and light.

In hot and humid Australian climates, keep medicines in a cool, dry place away from bathrooms and direct sunlight.

  • Keep in original packaging with label intact.
  • Do not store in glovebox or car where temperatures can exceed recommended ranges.
  • Keep out of reach of children in a childproof container.

Cold‑Chain Handling For Pharmacies

No cold chain is required for cyclobenzaprine; ambient storage as labelled is acceptable.

  • Pharmacies should monitor ambient temperatures and keep stock away from heat and moisture.
  • Check expiry dates and ensure dispensing labels include warnings about sedation and driving.

Guidelines For Proper Use (Australian Pharmacist Counselling Style)

Key Counselling Points For Pharmacists

Explain that the medicine is intended for short‑term relief of acute muscle spasm, usually for 7–21 days only.

Advise dosing, maximum duration, and common adverse effects such as drowsiness and dry mouth.

Highlight key interactions including MAOIs, serotonergic drugs and other CNS depressants, and warn against alcohol.

  • Contraindications to review: cardiac disease, severe hepatic impairment, recent MAOI use, known allergy.
  • Red flags requiring urgent review: palpitations, chest pain, severe confusion, fainting, seizure.
  • Document counselling and agree a follow‑up check within one week to assess efficacy and adverse effects.

Patient Advice From PBS/National Health Authorities

Encourage medication review in older patients and those on multiple medicines to reduce anticholinergic load.

Consider alternatives if the patient is elderly, has polypharmacy, or has cardiac or severe hepatic disease.

  • Advise patients to stop the medicine and seek urgent care for serious adverse signs such as severe dizziness, chest pain or palpitations.
  • Ask patients to report daytime drowsiness that affects work or driving immediately.

Delivery Across Australia

City Region Delivery Time
Sydney New South Wales 9-14 days
Melbourne Victoria 9-14 days
Brisbane Queensland 9-14 days
Perth Western Australia 9-14 days
Adelaide South Australia 9-14 days
Canberra Australian Capital Territory 9-14 days
Hobart Tasmania 9-14 days
Gold Coast Queensland 9-14 days
Newcastle New South Wales 9-14 days
Wollongong New South Wales 9-14 days
Townsville Queensland 14-21 days
Bundaberg Queensland 14-21 days
Albury New South Wales/Victoria 14-21 days
Kalgoorlie Western Australia 14-21 days

Final Safety Reminders

Flexeril (cyclobenzaprine) is not TGA‑approved in Australia; local clinicians and pharmacists should favour TGA‑approved and PBS‑listed alternatives for routine care.

If a patient obtains cyclobenzaprine from overseas, ensure the prescriber documents rationale, advises on risks and monitors closely for sedation, anticholinergic effects and cardiac symptoms.

When counselling, use plain language, confirm understanding about driving and alcohol, and schedule a follow‑up to check effectiveness and tolerability.

For urgent concerns such as severe dizziness, chest pain, fainting or seizures, seek immediate medical attention or call emergency services.

Related products